PHARMAC is seeking feedback on a funding proposal involving five treatments for multiple sclerosis, including two new treatments that are not currently funded – natalizumab and fingolimod.

In summary, this proposal would result, from 1 November 2014, in:

• Natalizumab (Tysabri), supplied by Biogen, and fingolimod (Gilenya), supplied by Novartis, being funded in the community and in DHB hospitals subject to restrictions; and
• Changes to the restrictions for funded access, in the community and in DHB hospitals, for interferon beta-1-alpha (Avonex), interferon beta-1-beta (Betaferon) and glatiramer acetate (Copaxone).

For more details, go to: http://www.pharmac.health.nz/news/consultation-2014-08-07-mstreatments/